Bio Usawa
San Francisco, US · Founded 2023 · Delaware corporation
Find your way into Bio Usawa
13 people in our graph share verified history with the Bio Usawa team — schools, employers, funds. One of them is your warm intro.
Carlos Payaunlockedknows Menghis Bairu · together at Elan (overlapped)
×7knows the team · via Elan
×2knows the team · via Alzheon
knows the team · via HCP Cureblindness
knows the team · via Brainstorm Cell
Bio Usawa is a biotechnology company that develops and manufactures affordable monoclonal antibodies and biologic medicines, with a focus on bringing cancer and other therapies to patients in Africa and globally.
Founders & leadership
Bio Usawa was founded in 2023 by Menghis Bairu, Mengistu Bairu, and Denise Chin.
MB
Menghis BairuinCo-founder · President & CEOMenghis Bairu is a physician with over 30 years of experience in biotechnology, pharmaceuticals, and global health. He previously served as Executive Chairman of Treos Bio, Chief Medical Officer at Elan, and held leadership roles at Genentech and Serenus Biotherapeutics, and currently serves as Adjunct Professor at UCSF School of Medicine.
MB
Mengistu BairuCo-founder & CEO
DC
Denise ChinFounder & Board Member
JH
John HautmanExecutive
Board
RC
Richard ChinBoard director
VA
Vincent AncinettiBoard director
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 3 rounds · 2024–2025
▶$500KraisedJan 2026 · 7 investors · BiotechnologyRule 506(b)
▶$500KraisedJan 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard ChinDirector
- Vincent AncinettiDirector
- John HautmanExecutive Officer
- Menghis BairuExecutive Officer, Director
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$1.7MraisedDec 2025 · 25 investors · BiotechnologyRule 506(b)
▶$1.7MraisedDec 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard ChinDirector
- Menghis BairuExecutive Officer, Director
- John HautmanExecutive Officer
- Vincent AncinettiDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Minimum investment
- $5K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$403.9KraisedDec 2025 · 5 investors · BiotechnologyRule 506(b)
▶$403.9KraisedDec 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vincent AncinettiDirector
- Richard ChinDirector
- John HautmanExecutive Officer
- Menghis BairuExecutive Officer, Director
- Offering amount
- $403.9K
- Amount sold
- $403.9K
- Minimum investment
- $25K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Umoja Biopharma, Inc.4 shared keywordsUmoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.
Yemaachi Biotechnology3 shared keywordsYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
Nanoporetech3 shared keywordsOxford Nanopore offers educational programs and tools to make DNA sequencing accessible to students and educators from high school through undergraduate levels. The company works with institutions and scientific educators to integrate nanopore sequencing technology into classroom settings and address the world's pressing challenges.
Thumbnail for Seragon Pharmaceuticals3 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Companies competing with Bio Usawa for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Bio Usawa do?
- Bio Usawa is a biotechnology company that develops and manufactures affordable monoclonal antibodies and biologic medicines, with a focus on bringing cancer and other therapies to patients in Africa and globally.
- Who founded Bio Usawa?
- Bio Usawa was founded by Menghis Bairu, Mengistu Bairu, Denise Chin in 2023.
- How much funding has Bio Usawa raised?
- Bio Usawa has disclosed $2.6M raised across 3 rounds.
- Where is Bio Usawa headquartered?
- Bio Usawa is headquartered in San Francisco, US.